Overall, our data point to an oncogenic role for CDK13 in thyroid cancer, as the ADAR1-dependent editing of CDK13 provides an advantage for cancer progression and may explain the global change in splicing pattern observed upon ADAR1 knockdown. This evidence concerns the gene CDK13 and thyroid cancer.